Authors: Lawrence, D Shahrokh, Z Marsters, S Achilles, K Shih, D Mounho, B Hillan, K Totpal, K DeForge, L Schow, P Hooley, J Sherwood, S Pai, R Leung, S Khan, LL Gliniak, B Bussiere, J Smith, CA Strom, SS Kelley, S Fox, JA Thomas, D Ashkenazi, A

Citation: D. Lawrence et al., Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions, NAT MED, 7(4), 2001, pp. 383-385

Authors: Kelley, SK Harris, LA Xie, D Deforge, L Totpal, K Bussiere, J Fox, JA

Citation: Sk. Kelley et al., Preclinical studies to predict the disposition of Apo2L/tumor necrosis factor-related apoptosis-inducing ligand in humans: Characterization of in vivo efficacy, pharmacokinetics, and safety, J PHARM EXP, 299(1), 2001, pp. 31-38

Authors: Ashkenazi, A Pai, RC Fong, S Leung, S Lawrence, DA Masters, SA Blackie, C Chang, L McMurtrey, AE Hebert, A DeForge, L Koumenis, IL Lewis, D Harris, L Bussiere, J Koeppen, H Shahrokh, Z Schwall, RH

Citation: A. Ashkenazi et al., Safety and antitumor activity of recombinant soluble Apo2 ligand, J CLIN INV, 104(2), 1999, pp. 155-162